Highlights
IIA supported (ever)1 patent
About
Cell Therapies for Neurodegenerative and Metabolic Diseases
NewCelX is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company’s integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes.
Identity
| Name | NewCelX |
|---|---|
| Slug | newcelx |
| Former names | Kadimastem |
| Type / kind | startup |
| Crunchbase ID | kadimastem |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6Tz4AKDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Oct, 2025; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Pinhas Sapir St 7, Ness Ziyyona, Israel |
Web & social
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharma-companiesstem-cellsdiabetesdegenerative-diseasesbioprocessneurologycell-therapyregenerative-medicinebiological-therapyamyotrophic-lateral-sclerosis-als
Funding
| Total raised | $45.4M |
|---|---|
| Current stage | Mature |
| Market cap | $8.7M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}